James Hallifax, The Psychedelic Investor, shares the two things he looks at when evaluating a medicinal psychedelic company.
Similar Posts
Interview with James Lanthier, CEO of Mindset Pharma
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
I Tried 5-MeO-DMT at a Psychedelic Retreat. This is MY Story
Have you ever considered taking 5-MeO-DMT, also known as Bufo…
Numinus Wellness CEO Discusses MAPS Partnership & How Psychedelics Will Change Society
In this episode James, from The Psychedelic Investor, sits down…
The Revolution in Mental Health Care: Psychedelics | PSILERA
In today’s episode, we speak with the leaders of Psilera…
High Doses, Crystals, and the Dangers of Corporate Takeover with Acacea Lewis
Acacea Lewis shares insights accrued from her extensive experience supporting people doing high dose journey work and integration.
Interview With Dr. Steven Mandel
In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.